Mitochondrial Support Template v1
approvedv1.0.0mitochondrial support · support mitochondria · approved by martin@gettetonlabs.com
Provider-only template. Not patient-visible. Dosing is source-attributed or a justified provider override. Approval requires safety + monitoring summaries; high/critical safety rules require acknowledgment.
💉 Dosing schedule
All component dosing in one place — verbatim from source or a justified provider override. Not a recommendation. Edit per component below.
| Component | Dose | Route | Frequency | Duration | Cycle | Source |
|---|---|---|---|---|---|---|
| SS-31primary | Investigational; commonly studied at 40 mg SC daily - provider-directed | subcutaneous | once daily (study protocols) | Per provider/study protocol | Per provider/study protocol | Practitioner Peptide Dosing Reference (commonly published ranges)Provider-reviewed |
| Reconstitution: Reconstitute per compounding pharmacy instructions | ||||||
| MOTS-csupport | 5-10 mg SC 2-3 times weekly | subcutaneous | 2-3 times weekly | 4 weeks | 4-week cycles | Practitioner Peptide Dosing Reference (commonly published ranges)Provider-reviewed |
| Reconstitution: Reconstitute with bacteriostatic water | ||||||
Template details
Components
2SS-31primarysrc: Practitioner Peptide Dosing Reference (commonly published ranges)
MOTS-csupportsrc: Practitioner Peptide Dosing Reference (commonly published ranges)
Safety rules
- caution · Introduce one agent at a time and titrate slowly. (inform provider)
Monitoring requirements
- symptom · Fatigue / PEM · Weekly · required
- functional · Exercise tolerance · Monthly
Evidence links
1 link(s) attached.
Audit history (3)
- 2026-06-15 04:06:55 · add_evidence_link by provider
- 2026-06-14 19:46:57 · approve_template by martin@gettetonlabs.com — Approved per provider instruction
- 2026-06-14 19:38:38 · create_template by seed-pack-v1 — Seed Pack v1 (draft)